US · Healthcare · Biotechnology
EPS came in at -0.81 against a street estimate of 1.00 — a miss of 181.0%.
Analysts rate Dianthus Therapeutics Inc. a strong buy (18 buy, 0 hold, 0 sell out of 18) with an average price target of $139.06.
| Fund | Stake |
|---|---|
| FMR Inc | 14.66% |
| BlackRock Inc | 7.37% |
| T. Rowe Price Investment Management,Inc. | 6.95% |
| Wellington Management Company LLP | 5.77% |
| Fairmount Funds Management LLC | 4.54% |
| T. Rowe Price Associates, Inc. | 4.50% |
| State Street Corp | 4.21% |
| Vanguard Capital Management, LLC | 3.86% |
| Document | Date |
|---|---|
| Quarterly report · Q3 2026 HEADLINE NUMBERS • Dianthus Therapeutics is a clinical-stage biotechnology company developing treatments for severe autoimmune diseases. • For the n | 2026-11-04 |
| Results announced · Q4 2026 HEADLINE NUMBERS • Cash, cash equivalents and investments were approximately $1.2 billion as of September 30, 2026, with expected runway into 2030. | 2026-11-04 |
| Quarterly report · Q2 2026 DIANTHUS THERAPEUTICS, INC. – 10-Q SUMMARY (Q2 2026) HEADLINE NUMBERS • Cash & Investments: Total liquid assets of $1,190.4 million as of June 30, 2 | 2026-08-04 |
| Results announced · Q3 2026 DIANTHUS THERAPEUTICS Q2 2026 FINANCIAL RESULTS SUMMARY HEADLINE NUMBERS • Cash position: Approximately $1.2 billion in cash, cash equivalents, and | 2026-08-04 |
| Company announcement · Q2 2026 DIANTHUS THERAPEUTICS, INC. - 8-K SUMMARY HEADLINE NUMBERS • Company: Dianthus Therapeutics, Inc. (ticker: DNTH, Nasdaq Capital Market) • Report dat | 2026-06-12 |
| Shareholder vote results · Q2 2026 DIANTHUS THERAPEUTICS, INC. - 8-K SUMMARY HEADLINE NUMBERS • Annual Meeting of Stockholders held on May 21, 2026 • Company trades on Nasdaq Capital | 2026-05-22 |
| Quarterly report · Q1 2026 DIANTHUS THERAPEUTICS, INC. – Q1 2026 SUMMARY HEADLINE NUMBERS • Cash and cash equivalents: $627.7 million at March 31, 2026, vs. $51.1 million at D | 2026-05-05 |
| Results announced · Q2 2026 DIANTHUS THERAPEUTICS Q1 2026 FINANCIAL RESULTS SUMMARY HEADLINE NUMBERS • Cash position: approximately $1.2 billion as of March 31, 2026 (comprised | 2026-05-05 |
Readable in the app.
| Announcement | Date |
|---|---|
| Phase 3 trial initiation mid-2026, top-line results anticipated 2H'28 Dianthus Therapeutics, a biotech company developing autoimmune disease treatments, announced significant clinical and financial progress. The company's lead drug, claseprubart, exceeded expe | 2026-05-05 |
| GO decision for Phase 3 CAPTIVATE trial; Q2'26 guidance based on interim analysis Dianthus Therapeutics announced a major milestone: an early GO decision for its Phase 3 CAPTIVATE trial of claseprubart in CIDP (Chronic Inflammatory Demyelinating Polyneuropathy). The compa | 2026-03-09 |
Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for Dianthus Therapeutics Inc. — free to start.
Open in the appGoogle PlayApp StoreData updated 2026-11-07.